Rubicon Genomics Product Helps Track Resistance Of Cancer Drugs
ANN ARBOR ? Rubicon Genomics reported that its ThruPLEXTM-FD Prep Kits contributed to the success of a breakthrough study recently published in Nature1 that showed that genomic data extracted from the plasma of cancer patients can be used to track drug resistance and potentially guide treatment. The proof-of-principle study showed that by sequencing tumor exomes